ArticleInternational journal of clinical and experimental medicine2015
Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center.International journal of molecular sciences · 2026Article
- Dermatofibrosarcoma Protuberans: The Impact of the Surgical Incision Site in Relation to Tumor Recurrence.Cureus · 2024Review
- A case report of abdominal metastatic dermatofibrosarcoma protuberans misdiagnosed as gastrointestinal stromal tumor.Diagnostic pathology · 2024Article
- Multi-omic profiling and real time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation.Human cell · 2023Article
- Metastatic orbital dermatofibrosarcoma protuberans fibrosarcomatous variant treated with radiotherapy.JAAD case reports · 2022Article
- Malignant Superficial Mesenchymal Tumors in Children.Cancers · 2022Review
- Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas.Frontiers in oncology · 2022Review
- Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line.Human cell · 2020Article
- Review
- Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report.Annals of translational medicine · 2019Article
- Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.Current treatment options in oncology · 2019Review
- Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.BMC cancer · 2018Article
- A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure.OncoTargets and therapy · 2018Article
- Dermatofibrosarcoma Protuberans.Current treatment options in oncology · 2017Review
- Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.BMC medicine · 2017Review
- From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib.Frontiers in pharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the efficacy and adverse effects of Imatinib therapy to advanced Dermatofibrosarcoma protuberan (DFSP) and Sunitinib therapy to advanced Dermatofibrosarcoma protuberan (DFSP) after Imatinib resistance.
methodsWe analyzed the efficacy, adverse effects and survival of 95 patients with locally advanced or metastatic DFSP treated by Imatinib between January 2003 and December 2009, and also analyzed the efficacy and adverse effects of 30 patients after Imatinib failure between January 2008 and December 2011.
resultsIn all 95 patients treated by Imatinib, 16 had complete response (CR, 16.8%), 44 had partial response (PR, 46.3%), 23 had stable disease (SD, 24.2%) and 12 had progressive disease (PD, 12.6%). The DCR (CR+PR+SD) was 87.4%. The median PFS was 23 months and the OS was 40 months. For 30 patients had Sunitinib treatment after Imatinib failure, 2 had CR (6.7%), 10 had PR (33.3%), 12 had SD (40%) and 6 had PD (20%). The disease control rate (DCR=CR+PR+SD) was 73.3%. The progression free survival (PFS) of CR and PR patients were 22 months and 20 months respectively. The PFS of 12 SD was 18 months, and overall survival (OS) was 28 months. And the median PFS and OS of all 30 patients were 19 and 27 months respectively after Sunitinib treatment. Most of the Imatinib-induced adverse effects are of grade 1-2, including nausea, water retention/edema, fatigue, etc.
conclusionImatinib has been proven to be effective and well-tolerated in the treatment of locally advanced or inoperable patients with DFSP. After Imatinib failure, Sunitinib therapy showed good clinical efficacy and tolerated adverse effects as a new treatment option for such patients.
Indexed as
Identifiers
26221412PMC4509357W2410936837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.